ASCO 2013 - Poster: A phase II multicenter study of the investigational single agent orteronel (TAK-700) in non-metastatic castration-resistant prostate cancer (nmCRPC [M0]) and rising prostate-specific antigen (PSA)

CHICAGO, IL USA ( - Presented by Maha Hussain,1 Paul Corn,2 Dror Michaelson,3 Hans Hammers,4 Joshi Alumkal,5 Charles Ryan,6 Justine Bruce,7 Susan Moran,8 David Maclean,8 Shih-Yuan Lee,8 H Mark Lin,8 Yanyan Zhu,8 Hongliang Shi,8 Peter Mortimer,9 and Daniel George10 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

asco 2013 hussain poster 5076 thumb

1University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; 2M.D. Anderson Cancer Center, Houston, TX, USA; 3Massachusetts General Hospital Cancer Center, Boston, MA, USA; 4Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; 5Oregon Health & Science University, Portland, OR, USA; 6UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; 7University of Wisconsin Carbone Cancer Center, Madison, WI, USA; 8Millennium: The Takeda Oncology Company, Cambridge, MA, USA; 9Takeda Global Research & Development Centre (Europe) Ltd, London, UK; 10Duke University Medical Center, Durham, NC, USA and Members of the Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation


The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

asco x

View Full ASCO 2013 Coverage